Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
12
12
3
11
12
1
Research & Development
18
21
17
15
12
12
Operating Expenses
31
34
33
26
26
25
Other Non Operating Income (Expenses)
0
--
--
--
--
--
Pretax Income
-30
-31
-27
-24
-26
-22
Income Tax Expense
0
0
0
0
0
0
Net Income
-30
-31
-27
-24
-26
-22
Net Income Growth
7%
15%
13%
-8%
18%
-33%
Shares Outstanding (Diluted)
90.99
76.48
67.62
58.03
53.51
40.34
Shares Change (YoY)
20%
13%
17%
8%
33%
82%
EPS (Diluted)
-0.33
-0.41
-0.41
-0.43
-0.49
-0.56
EPS Growth
-13%
1%
-5%
-12%
-13%
-63%
Free Cash Flow
-24
-27
-28
-23
-22
-22
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-31
-34
-33
-26
-26
-25
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
-31
-34
-33
-26
-26
-25
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Oncolytics Biotech Inc.'s key financial statements?
According to the latest financial statement (Form-10K), Oncolytics Biotech Inc. has a total asset of $20, Net loss of $-31
What are the key financial ratios for ONCY?
Oncolytics Biotech Inc.'s Current ratio is 1.42, has a Net margin is 0, sales per share of $0.
How is Oncolytics Biotech Inc.'s revenue broken down by segment or geography?
Oncolytics Biotech Inc. largest revenue segment is Banking, at a revenue of 489,362,000 in the most earnings release.For geography, United States is the primary market for Oncolytics Biotech Inc., at a revenue of 693,750,000.
Is Oncolytics Biotech Inc. profitable?
no, according to the latest financial statements, Oncolytics Biotech Inc. has a net loss of $-31
Does Oncolytics Biotech Inc. have any liabilities?
yes, Oncolytics Biotech Inc. has liability of 14
How many outstanding shares for Oncolytics Biotech Inc.?
Oncolytics Biotech Inc. has a total outstanding shares of 80.02